Holy Name Medical Center

The trials here

What the 22 trials at this site are about, from their registry records.

Conditions

• Peripheral artery disease7 trials
• Ovarian cancer4 trials
• Endometrial cancer3 trials
• Multiple sclerosis3 trials
• Lung cancer2 trials
• Atrial fibrillation1 trial
• Coronary artery disease1 trial
• Crohn's disease1 trial
• Type 2 diabetes1 trial

Phase

• Phase 39 trials
• Phase 24 trials
• Phase 2/31 trial

Status

• Active, not recruiting8 trials
• Completed8 trials
• Recruiting5 trials
• Terminated1 trial

Lead sponsor

• Genmab2 trials
• Janssen Research & Development, LLC2 trials
• Abbott Medical Devices1 trial
• AbbVie1 trial
• Banner Life Sciences LLC1 trial
• and 15 more

Running trials

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· Phase 3· Genmab· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Diome Kramer

• Active, not recruiting

  Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

  NCT06619236· Phase 3· Genmab· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

  NCT06564311· Phase 2· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

  NCT05659381· Phase 3· GOG Foundation· Source

  Contact: Marissa Van Orden

• Recruiting

  A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

  NCT06112418· Cleerly, Inc.· Source

  Contact: Jaffar Raza, MD

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  SELUTION4SFA Trial

  NCT05132361· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  MOTIV BTK Randomized Controlled Trial

  NCT05406622· REVA Medical, Inc.· Source

• Recruiting

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  NCT04613596· Phase 2/3· Mirati Therapeutics Inc.· Source

  Contact: Yadyra Rivera, Site 007-784

• Active, not recruiting

  Abemaciclib and Letrozole to Treat Endometrial Cancer

  NCT04393285· Phase 2· Gynecologic Oncology Group· Source

• Active, not recruiting

  LIFE-BTK Randomized Controlled Trial

  NCT04227899· Abbott Medical Devices· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Multiple sclerosis1 recruiting
• Ovarian cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice

  NCT05978531· Banner Life Sciences LLC· Source

• Recruiting

  PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

  NCT05313165· LimFlow, Inc.· Source

  Contact: Erin Towery

• Completed

  A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

  NCT05358353· ReFlow Medical, Inc.· Source

• Completed

  Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

  NCT04374630· Phase 2· Laekna Limited· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Completed

  The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

  NCT03551496· Phase 3· Boston Scientific Corporation· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Eisai Inc.· Source

• Completed

  Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

  NCT03241459· SurModics, Inc.· Source